TAS-102 in Treating Advanced Biliary Tract Cancers
Status:
Active, not recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent
TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread
to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil
hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading.